The miRNome of canine invasive urothelial carcinoma

Urothelial carcinoma (UC) comprises up to 2% of all naturally occurring neoplasia in dogs and can be challenging to diagnose. MicroRNAs (miRNAs) have been reported to be dysregulated in numerous diseases, including neoplasia. MiRNA expression has been evaluated in human UC, but there is limited information regarding the miRNA transcriptome of UC in dogs. Our study aimed to evaluate differential miRNA expression in bladder tissue collected from normal canine urothelium and canine invasive UC (iUC) to elucidate the dysregulated pathways in canine UC. Next-Generation RNA sequencing (RNA-Seq) was performed for dogs with UC (n = 29) and normal canine urothelium (n = 4). Raw RNA data were subjected to normalization, and pairwise comparison was performed using EdgeR with Benjamini-Hochberg FDR multiple testing correction (p < 0.05; >2-fold change) comparing tissue samples of normal urothelium to canine iUC samples. Principal component analysis and hierarchical cluster analysis were performed. MiRNA of FFPE tissue samples of separate iUC (n = 5) and normal urothelium (n = 5) were used to evaluate five miRNAs using RT-qPCR. Pathway analysis was performed utilizing miRWalk, STRING database, and Metascape utilizing KEGG pathways and GO terms databases. Twenty-eight miRNAs were differentially expressed (DE) by RNA-Seq. RT-qPCR confirmed that four miRNAs are significantly downregulated in UC compared to healthy urothelial samples (miR-105a, miR-143, miR-181a, and miR-214). Principal component analysis and hierarchical cluster analysis showed separation between miRNAs in iUC and the control group. The DE miRNAs are most often associated with gene silencing by miRNA, miRNAs in cancer, and miRNAs involved in DNA damage responses. Proteins involved include HRAS, KRAS, ARAF, RAF1, MAPK1, MAP2K1, MAPK3, FGFR3, EGFR, HBEGF, RASSF1, E2F2, E2F3, ERBB2, SRC, MMP1, and UP3KA. The differential expression of miRNAs in canine iUC compared to normal canine urothelial tissue indicates that these markers should be further evaluated for their potential role as diagnostic and therapeutic targets.

[1]  Sagar M. Utturkar,et al.  Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma , 2021, Molecular Cancer Therapeutics.

[2]  Sagar M. Utturkar,et al.  Basal and Luminal Molecular Subtypes in Naturally-Occurring Canine Urothelial Carcinoma are Associated with Tumor Immune Signatures and Dog Breed , 2021, Bladder cancer.

[3]  D. Gustafson,et al.  Characterizing the Molecular and Immune Landscape of Canine Bladder Cancer. , 2021, Veterinary and comparative oncology.

[4]  A. Azmi,et al.  microRNA‐based diagnostic and therapeutic applications in cancer medicine , 2021, Wiley interdisciplinary reviews. RNA.

[5]  B. Saunders,et al.  Targets and regulation of microRNA-652-3p in homoeostasis and disease , 2021, Journal of Molecular Medicine.

[6]  Nadezhda T. Doncheva,et al.  The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..

[7]  Y. Allory,et al.  Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer , 2020, Scientific Reports.

[8]  T. Morikawa,et al.  A REAPPRAISAL , 2020, The Eudemian and Nicomachean Ethics.

[9]  Sung Han Kim,et al.  Review of non-invasive urinary biomarkers in bladder cancer , 2020, Translational cancer research.

[10]  H. Zhang,et al.  MiR-214 promotes proliferation and inhibits apoptosis of oral cancer cells through MAPK/ERK signaling pathway. , 2020, European review for medical and pharmacological sciences.

[11]  J. Collier,et al.  A novel, safe, fast and efficient treatment for Her2‐positive and negative bladder cancer utilizing an EGF‐anthrax toxin chimera , 2019, International journal of cancer.

[12]  Aimin Li,et al.  MiR-532-3p suppresses colorectal cancer progression by disrupting the ETS1/TGM2 axis-mediated Wnt/β-catenin signaling , 2019, Cell Death & Disease.

[13]  Ryan C. Gimple,et al.  RAS: Striking at the Core of the Oncogenic Circuitry , 2019, Front. Oncol..

[14]  M. Breen,et al.  Novel Noninvasive Diagnostics. , 2019, The Veterinary clinics of North America. Small animal practice.

[15]  Shu Yang.  Flexible Imputation of Missing Data, 2nd ed. , 2019, Journal of the American Statistical Association.

[16]  Olga Tanaseichuk,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[17]  Wei Chen,et al.  Downregulation of microRNA-532-5p promotes the proliferation and invasion of bladder cancer cells through promotion of HMGB3/Wnt/β-catenin signaling. , 2019, Chemico-biological interactions.

[18]  Carsten Sticht,et al.  miRWalk: An online resource for prediction of microRNA binding sites , 2018, PloS one.

[19]  D. Dhawan,et al.  Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer , 2018, PLoS genetics.

[20]  Wei Xue,et al.  MiR-532-5p suppresses renal cancer cell proliferation by disrupting the ETS1-mediated positive feedback loop with the KRAS-NAP1L1/P-ERK axis , 2018, British Journal of Cancer.

[21]  Guangquan Zhang,et al.  MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma , 2018, Cell Death & Disease.

[22]  G. T. Selvarajah,et al.  Comparative aspects of microRNA expression in canine and human cancers , 2018, Journal of veterinary science.

[23]  P. Ghosh,et al.  MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples , 2017, BMC Veterinary Research.

[24]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[25]  Wei Zhou,et al.  miR‐532 promoted gastric cancer migration and invasion by targeting NKD1 , 2017, Life sciences.

[26]  A. Shilatifard,et al.  The evolving genomic landscape of urothelial carcinoma , 2017, Nature Reviews Urology.

[27]  Yinghao Sun,et al.  DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis , 2016, PloS one.

[28]  A. Seth,et al.  MiR‐301a regulates E‐cadherin expression and is predictive of prostate cancer recurrence , 2016, The Prostate.

[29]  Fan Wang,et al.  High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in Ovarian Cancer Both In Vivo and In Vitro , 2016, Molecular Cancer Therapeutics.

[30]  M. Breen,et al.  Detection of BRAF Mutation in Urine DNA as a Molecular Diagnostic for Canine Urothelial and Prostatic Carcinoma , 2015, PloS one.

[31]  Z. Granot,et al.  Distinct Functions of Neutrophil in Cancer and Its Regulation , 2015, Mediators of inflammation.

[32]  D. Knapp,et al.  Management of transitional cell carcinoma of the urinary bladder in dogs: a review. , 2015, Veterinary journal.

[33]  S. Hammond.  An overview of microRNAs. , 2015, Advanced drug delivery reviews.

[34]  M. Breen,et al.  BRAF Mutations in Canine Cancers , 2015, PloS one.

[35]  A. Scorilas,et al.  Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. , 2015, Carcinogenesis.

[36]  Zuozhang Yang,et al.  MicroRNAs in apoptosis, autophagy and necroptosis , 2015, Oncotarget.

[37]  K. Reddy,et al.  MicroRNA (miRNA) in cancer , 2015, Cancer Cell International.

[38]  S. G. Shapiro,et al.  Canine urothelial carcinoma: genomically aberrant and comparatively relevant , 2015, Chromosome Research.

[39]  E. Ostrander,et al.  Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer—Evidence for a Relevant Model System and Urine-Based Diagnostic Test , 2015, Molecular Cancer Research.

[40]  Yu-Qin Wang,et al.  MiR-32 induces cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting PTEN , 2015, Tumor Biology.

[41]  J. Xiang,et al.  MiR-301a Promotes Colorectal Cancer Cell Growth and Invasion by Directly Targeting SOCS6 , 2015, Cellular Physiology and Biochemistry.

[42]  S. Jiang,et al.  Downregulated miR329 and miR410 promote the proliferation and invasion of oral squamous cell carcinoma by targeting Wnt-7b. , 2014, Cancer research.

[43]  Tianxing Ji,et al.  MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma. , 2014, Carcinogenesis.

[44]  Yu-Sun Chang,et al.  MicroRNA-205 Targets Tight Junction-related Proteins during Urothelial Cellular Differentiation * , 2014, Molecular & Cellular Proteomics.

[45]  M. Manns,et al.  An Extended ΔCT-Method Facilitating Normalisation with Multiple Reference Genes Suited for Quantitative RT-PCR Analyses of Human Hepatocyte-Like Cells , 2014, PloS one.

[46]  W. Guan,et al.  Identification of suitable reference genes for hepatic microRNA quantitation , 2014, BMC Research Notes.

[47]  Lei Zhang,et al.  MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6). , 2014, Biochemical and biophysical research communications.

[48]  N. Seki,et al.  The MicroRNA Expression Signature of Bladder Cancer by Deep Sequencing: The Functional Significance of the miR-195/497 Cluster , 2014, PloS one.

[49]  J. Lozano,et al.  Using microRNA profiling in urine samples to develop a non‐invasive test for bladder cancer , 2013, International journal of cancer.

[50]  Jeffrey E. Jarrett.  Book Reviews , 2013 .

[51]  M. A. Cabrita,et al.  miR-105 Inhibits Prostate Tumour Growth by Suppressing CDK6 Levels , 2013, PloS one.

[52]  Ricardo J. G. B. Campello,et al.  Proximity Measures for Clustering Gene Expression Microarray Data: A Validation Methodology and a Comparative Analysis , 2013, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[53]  S. Masters,et al.  miR‐223: infection, inflammation and cancer , 2013, Journal of internal medicine.

[54]  Yu Zhou,et al.  MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells , 2013, Molecular Cancer.

[55]  Qing Xu,et al.  Downregulation of miR-145 associated with cancer progression and VEGF transcriptional activation by targeting N-RAS and IRS1. , 2013, Biochimica et biophysica acta.

[56]  Y. Akao,et al.  Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. , 2013, Cancer letters.

[57]  J. Ju,et al.  Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer , 2013, Journal of Gastroenterology.

[58]  A. Lopez‐Beltran,et al.  Histologic grading of urothelial carcinoma: a reappraisal. , 2012, Human pathology.

[59]  E. Plimack,et al.  Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Michael S Kent,et al.  Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma. , 2012, American journal of veterinary research.

[61]  H. Mollenkopf,et al.  Reference miRNAs for miRNAome Analysis of Urothelial Carcinomas , 2012, PloS one.

[62]  B. Powell,et al.  Bone to pick: the importance of evaluating reference genes for RT-qPCR quantification of gene expression in craniosynostosis and bone-related tissues and cells , 2012, BMC Research Notes.

[63]  F. Slack,et al.  MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy , 2011, Nature Reviews Cancer.

[64]  T. Ørntoft,et al.  The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer , 2011, British Journal of Cancer.

[65]  John S. Condeelis,et al.  Chemotaxis in cancer , 2011, Nature Reviews Cancer.

[66]  Jing Chen,et al.  MicroRNA Expression Signatures of Bladder Cancer Revealed by Deep Sequencing , 2011, PloS one.

[67]  F. Valent,et al.  Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study. , 2011, Urologic oncology.

[68]  Zhongxin Lu,et al.  miR‐301a as an NF‐κB activator in pancreatic cancer cells , 2011, The EMBO journal.

[69]  Shu Liu,et al.  Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. , 2010, Genes & development.

[70]  B. Pützer,et al.  Checks and balances: E2F—microRNA crosstalk in cancer control , 2010, Cell cycle.

[71]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[72]  Saiful Miah,et al.  Distinct microRNA alterations characterize high- and low-grade bladder cancer. , 2009, Cancer research.

[73]  Xue-Ru Wu,et al.  Uroplakins in urothelial biology, function, and disease. , 2009, Kidney international.

[74]  D. Dhawan,et al.  Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer. , 2009, Urologic oncology.

[75]  Q. Pan,et al.  MicroRNA-143 as a tumor suppressor for bladder cancer. , 2009, The Journal of urology.

[76]  D. Spandidos,et al.  Mutational Analysis of the BRAF Gene in Transitional Cell Carcinoma of the Bladder , 2009 .

[77]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[78]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.

[79]  A. Harris,et al.  Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.

[80]  C. Dinney,et al.  Growth factors and receptors as prognostic markers in urothelial carcinoma , 2008, Current urology reports.

[81]  C. Cooper,et al.  Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells , 2007, Oncogene.

[82]  A. Kimchi,et al.  DAPk Protein Family and Cancer , 2006, Autophagy.

[83]  Claus Lindbjerg Andersen,et al.  Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets , 2004, Cancer Research.

[84]  J. Behrens,et al.  The Wnt signaling pathway and its role in tumor development , 2003, Journal of Cancer Research and Clinical Oncology.

[85]  D. Knapp,et al.  Canine transitional cell carcinoma. , 2003, Journal of veterinary internal medicine.

[86]  M. Miller,et al.  Immunohistochemical Detection of Uroplakin III, Cytokeratin 7, and Cytokeratin 20 in Canine Urothelial Tumors , 2003, Veterinary pathology.

[87]  M. Dietel,et al.  Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. , 2000, American journal of clinical pathology.

[88]  N. Seki,et al.  Role of pre-miR-532 (miR-532-5p and miR-532-3p) in regulation of gene expression and molecular pathogenesis in renal cell carcinoma. , 2019, American journal of clinical and experimental urology.

[89]  David Brink,et al.  : A Review of the , 2018 .

[90]  W. Huber,et al.  Analyzing RNA-seq data with DESeq 2 ( PDF ) , 2017 .

[91]  D. Dhawan,et al.  Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development. , 2014, ILAR journal.

[92]  Hong-zhao Li,et al.  Differential miRNA expression profiles in bladder urothelial carcinomas. , 2010, Asian Pacific journal of cancer prevention : APJCP.

[93]  M. Gerstein,et al.  RNA-Seq: a revolutionary tool for transcriptomics , 2009, Nature Reviews Genetics.

[94]  M. Kanehisa,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[95]  R. Darveau.  Infection, inflammation, and cancer , 1999, Nature Biotechnology.

[96]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..